OCS-05 therapy for MS safe and neuroprotective.
OCS-05, a neuroprotective treatment candidate for multiple sclerosis (MS) or other causes of optic nerve inflammation, has shown a favorable safety and pharmacological profile in healthy volunteers, according to Phase 1 trial data. A Phase 2 trial is now evaluating OCS-05’s safety and effectiveness in people with acute optic neuritis due to MS, myelin oligodendrocyte glycoprotein antibody-associated disease, or an unknown cause. The trial will assess changes in eye health, visual acuity, and overall disability.